STOCK TITAN
  1. Home
  2. Sec-filings
  3. CNTA
  4. [144] Centessa Pharmaceuticals plc American SEC Filing

[144] Centessa Pharmaceuticals plc American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock CNTA logo
Centessa Pharmaceuticals Plc

NASDAQ:CNTA

CNTA Rankings

#2712 Ranked by Market Cap
N/A Ranked by Dividends

CNTA Latest News

Jun 16, 2025
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
May 19, 2025
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 14, 2025
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
Mar 24, 2025
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
Mar 6, 2025
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

CNTA Latest SEC Filings

Jul 17, 2025
[144] Centessa Pharmaceuticals plc American SEC Filing
Jul 17, 2025
[Form 4] Centessa Pharmaceuticals plc American Insider Trading Activity
Jul 15, 2025
[144] Centessa Pharmaceuticals plc American SEC Filing
Jun 25, 2025
[Form 4] Centessa Pharmaceuticals plc American Insider Trading Activity
Jun 25, 2025
[Form 4] Centessa Pharmaceuticals plc American Insider Trading Activity

CNTA Stock Data

1.87B
118.69M
1.29%
97.12%
4.14%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
ALTRINCHAM, CHESHIRE